Proteins

Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα.

Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment.

Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody.

Vonsetamig is a humanised immunoglobulin G4-kappa, anti-TNFRSF17 and CD3E monoclonal antibody.

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma.

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4.

Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF).

Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells.

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells.

Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis.

Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells.

Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator.

Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 ).

Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4).

Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research.

Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells.

Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation.

Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.

Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3.

Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors.

Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab.

Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 , via a cleavable linker.

Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody.

Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker.